Davor Štimac

Prof. Dr. Davor Štimac

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
SMSandra Milić
Sandra Milić
DLDavorka Lulić
Davorka Lulić
DŠDavor Štimac
Davor Štimac
Laparoscopic surgery is the main treatment method for patients with gastrointestinal malignant tumors. Although laparoscopic surgery is minimally invasive, its tool stimulation and pneumoperitoneum pressure often cause strong stress reactions in patients. On the other hand, gastrointestinal surgery can cause stronger pain in patients, compared to other surgeries. Transversus abdominis plane block (TAPB) can effectively inhibit the transmission of nerve impulses caused by surgical stimulation, alleviate patient pain, and thus alleviate stress reactions. Remazolam is an acting, safe, and effective sedative, which has little effect on hemodynamics and is suitable for most patients. TAPB combined with remazolam can reduce the dosage of total anesthetic drugs, reduce adverse reactions, reduce stress reactions, and facilitate the rapid postoperative recovery of patients.

2 March 2015 in Nature Immunology
Verified
Journal Article
Closed access
FWFelix Martinus Wensveen
Felix Martinus Wensveen
VJVedrana Jelenčić
Vedrana Jelenčić
SVSonja Valentić
Sonja Valentić
MŠMarko Šestan
Marko Šestan
TWTamara Turk Wensveen
Tamara Turk Wensveen
BPBojan Polić
Bojan Polić

1 July 2014 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
DLDouglas R. LaBrecque
Douglas R. LaBrecque
ZAZaigham Abbas
Zaigham Abbas
FAFrank Anania
Frank Anania
PFPeter Ferenci
Peter Ferenci
AKAamir G. Khan
Aamir G. Khan
ALAnton LeMair
Anton LeMair

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
IMIvana Mikolasevic
Ivana Mikolasevic
LOLidija Orlic
Lidija Orlic
NFNeven Franjic
Neven Franjic
GHGoran Hauser
Goran Hauser
DSDavor Stimac
Davor Stimac
SMSandra Milic
Sandra Milic
Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

22 June 2016 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
SMSandra Milić
Sandra Milić
IMIvana Mikolasevic
Ivana Mikolasevic
LOLidija Orlic
Lidija Orlic
EDEdita Devcic
Edita Devcic
NCNada Starcevic Cizmarevic
Nada Starcevic Cizmarevic
SRSmiljana Ristić
Smiljana Ristić
The liver plays a major role in iron homeostasis; thus, in patients with chronic liver disease, iron regulation may be disturbed. Higher iron levels are present not only in patients with hereditary hemochromatosis, but also in those with alc...

1 June 2012 in Digestive Diseases
Verified
Journal Article
Closed access
SMSandra Milić
Sandra Milić
DŠDavor Štimac
Davor Štimac
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic hepatic disorder in Western countries, with a prevalence of 20–30%. NAFLD comprises ‘silent liver disease’, in which simple steatosis is the only histological finding and which is benign in course, and nonalcoholic steatohepatitis, which is characterized by hepatocellular injury and inflammation with or without fibrosis. NAFLD is clinically important, because even benign fatty liver can progress to steatohepatitis in many patients, which can lead to liver cirrhosis and its complications and hepatocellular carcinoma. NAFLD is a hepatic manifestation of metabolic syndrome; it is closely related to other clinical features of metabolic syndrome, and thus to cardiovascular morbidity. There are several different noninvasive techniques for formal diagnosis and follow-up, but liver biopsy remains the gold standard. The most important therapeutic strategies include lifestyle changes, including changes in dietary habits aimed at weight loss and blood pressure regulation, with a consequent decrease in insulin resistance. For some patients with NAFLD/nonalcoholic steatohepatitis, pharmacological treatment is the best option, although further studies are needed to confirm its efficacy and tolerability.